New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTSGYP, PRXLSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:18 EDTSGYPSynergy Pharmaceuticals files $250M mixed securities shelf
Subscribe for More Information
June 25, 2015
07:49 EDTPRXLPAREXEL shares should be bought on weakness, says Wells Fargo
Subscribe for More Information
June 24, 2015
07:26 EDTPRXLPAREXEL price target raised to $82 from $72 at UBS
UBS raised its price target on PAREXEL to $82 from $72 following the company's updated guidance. The firm sees gains from cost cutting, margin expansion and the growth of strategic partners. UBS reiterated its Buy rating on PAREXEL shares.
05:59 EDTSGYPStocks with implied volatility below IV index mean; SGYP WMB
Subscribe for More Information
June 23, 2015
16:18 EDTPRXLPAREXEL maintains mid-point of prior FY15 EPS guidance at $2.74
Subscribe for More Information
16:17 EDTPRXLPAREXEL to record $35M-$45M charge from restructuring
Subscribe for More Information
16:13 EDTPRXLPAREXEL sees double digit growth in EPS for 2016
Subscribe for More Information
16:11 EDTPRXLPAREXEL sees FY16 EPS $3.02-$3.38, consensus $3.24
Sees FY16 revenue $2.16B-$2.21B, consensus $2.2B.
16:10 EDTPRXLPAREXEL narrows FY15 EPS view to $2.70-$2.78 from $2.65-$2.83, consensus $2.75
Subscribe for More Information
16:06 EDTPRXLPAREXEL sees Q4 EPS 70c-78c, consensus 75c
Subscribe for More Information
10:30 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
09:14 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
06:36 EDTSGYPSynergy Pharmaceuticals volatility elevated
Subscribe for More Information
06:02 EDTSGYPSynergy Pharma begins second of two Phase 3 clinical trials of plecanatide
Synergy Pharmaceuticals announced the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation, or IBS-C. The phase 3 IBS-C program includes two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the U.S. and each trial is expected to enroll approximately 1050 adult patients with IBS-C.
June 22, 2015
15:41 EDTSGYPSynergy Pharmaceuticals volatility elevated on sharp rally
Synergy Pharmaceuticals July is at 134, October is at 95; compared to its 52-week range of 72 to 158; suggesting large near term price move movement.
10:21 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use